

Datasheet for ABIN935551

IGFBP6 Protein



Go to Product page

\sim	
Over	$\backslash \backslash \backslash \cap \backslash \backslash \backslash$
OVCI	VICVV

O V CI VIEVV	
Quantity:	20 μg
Target:	IGFBP6
Origin:	Human
Source:	Hi-5 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Product Details	
Sequence:	RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG
Characteristics:	Purified recombinant Human IGF BP6 protein Expression System: Hi-5 cells Bioactivity: Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 - 0.4 µg/mL.
Purity:	> 95 % pure
Endotoxin Level:	< 0.1 ng per μg (1 EU/μg).
Target Details	
Target:	IGFBP6

Target Details

Alternative Name:	IGF BP6 (IGFBP6 Products)
Background:	IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body
	fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid,
	and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent
	cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma.
	Alternative Names: IGF BP-6 protein, IBP-6 protein, IGF BP 6, IGF BP 6 protein, IGF BP-
	6 protein, IGF BP-6
Molecular Weight:	22.6 kDa
Pathways:	WNT Signaling, Myometrial Relaxation and Contraction
Application Details	
Application Notes:	Each Investigator should determine their own optimal working dilution for specific applications.
Comment:	Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for
	Plant Research, Inc.
Restrictions:	For Research Use only
Handling	
Format:	Lyophilized
Buffer:	Supplied as a lyophilized powder.
	2 SPP
Handling Advice:	Avoid repeated freeze/thaw cycles.
Handling Advice: Storage:	